The Hebrew University ranks 12th worldwide in biotechnology patents.
$2 billion in annual sales are generated from two life science products originating from scientific innovation at the Hebrew University of Jerusalem. These include Exelon (marketed by Novartis) for the treatment of Alzheimer’s disease and Doxil (marketed by J&J) for the treatment of cancer..
